Exact Sciences (STU:EXK) Additional Paid-In Capital : €6,174 Mil(As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Additional Paid-In Capital?

Exact Sciences's quarterly additional paid-in capital declined from Sep. 2023 (€6,128 Mil) to Dec. 2023 (€6,063 Mil) but then increased from Dec. 2023 (€6,063 Mil) to Mar. 2024 (€6,174 Mil).

Exact Sciences's annual additional paid-in capital increased from Dec. 2021 (€5,336 Mil) to Dec. 2022 (€5,958 Mil) and increased from Dec. 2022 (€5,958 Mil) to Dec. 2023 (€6,063 Mil).

Exact Sciences Additional Paid-In Capital Historical Data

The historical data trend for Exact Sciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Additional Paid-In Capital Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,065.80

3,517.61

5,335.54

5,958.19

6,062.50

Exact Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															5,974.62	5,977.11	6,128.32	6,062.50	6,173.83

Exact Sciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Exact Sciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Exact Sciences (STU:EXK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Additional Paid-In Capital

Comparable Companies

QGEN CRL MEDP NTRA RVTY RDNT SHC GH NEOG DGX TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN

Traded in Other Exchanges

EXAS:USA

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.